Advances in immunotherapy of hematologic malignancies.
The chimeric anti-CD20 antibody rituxamab, as well as radiolabeled anti-CD20 monoclonal antibodies, have demonstrated significant activity against B-cell non-Hodgkin's lymphoma. Idiotype vaccination in remission may prevent relapse in follicular non-Hodgkin's lymphoma. The campath-1H antibody has activity in chronic lymphocytic leukemia, and additional unconjugated, radiolabeled, and drug-conjugated monoclonal antibodies (anti-CD45 and anti-CD33) have shown activity in acute myeloid leukemia. Adoptive cellular therapy is active against posttransplantation relapse and lymphoproliferative disorders in most patients, and complications of graft-versus-host disease may be controlled by suicide gene transfection of the donor lymphocytes.
Maloney
D G
DG
Clinical Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D015703:Antigens, CD; D018951:Antigens, CD20 / Q000276:immunology; D019337:Hematologic Neoplasms / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000639:trends*; D017493:Leukocyte Common Antigens / Q000276:immunology; D051917:Leukosialin; D012795:Sialoglycoproteins / Q000276:immunology
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D018951:Antigens, CD20; D051917:Leukosialin; C465014:SPN protein, human; D012795:Sialoglycoproteins; D017493:Leukocyte Common Antigens